FDA Advisory Committee voted in support of favorable benefit-risk profile for Pfizer’s PAXLOVID
On Mar. 16, 2023, Pfizer announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee (AMDAC)…
Texas A&M scientists disable protective gene In mosquitoes
On Mar. 15, 2023, scientists at Texas A&M announced that a research study: ‘RNA interference is essential to…
‘Deaths of Despair’ contributed to 17% rise in Minnesota’s death rate during COVID-19 pandemic
On Mar. 13, 2023, Mayo Clinic published a study that showed the COVID-19 pandemic was linked to a…
Pfizer announced acquisition of Seattle-based Seagen for $43 billion
On Mar. 13, 2023, Pfizer announced an agreement to acquire Seagen, a global biotechnology company that discovers, develops…
Pfizer’s ZAVZPRET (zavegepant) Migraine Nasal Spray received FDA approval
On Mar. 10, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ZAVZPRET (zavegepant),…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Radiology | Therapeutics | Women's Health
FDA updated mammography regulations to require reporting of breast density information and facility oversight
On Mar. 9, 2023, the U.S. Food and Drug Administration (FDA) announced that it had published updates to…
Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal spray
On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval…
Outbreak of Blastomycosis reported in Michigan Mill workers
On Feb. 28, 2023, Public Health Delta & Menominee Counties (PHDM) was alerted to three cases of atypical…
Higher-Dose and longer duration of Ivermectin not effective with COVID-19
On Feb. 20, 2023, results from a randomized clinical trial of Ivermectin in a higher-hose and longer duration…
CPRIT approved $12 million to bring top-flight cancer researchers to Lone Star State
On Feb. 15, 2023, the Cancer Prevention and Research Institute of Texas (CPRIT) announced a major step forward…
Researchers document third known case of HIV remission involving stem cell transplant
On Feb. 15, 2023, it was reported that a 53-year-old man in Germany had become at least the…
British Columbia Institute of Technology received $14.5 million to support aerospace and life sciences training
On Feb. 14, 2023, the Pacific Economic Development Agency of Canada (PacifiCan), announced $14.5 million in funding for…
Biotechnology | Diagnostics | Genomics | NIH | Therapeutics
Large-scale genetic analysis showed microRNAs in human pancreas associated with diabetes
On Feb. 9, 2023, the National Institutes of Health (NIH) announced that a new large-scale genetic analysis found…
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics | WHO | Women's Health
WHO launched new roadmap on breast cancer
On Feb. 3, 2023, the World Health Organization (WHO) released an updated Global Breast Cancer Initiative (GBCI) Framework…
Biotechnology | Disease | NIH | Therapeutics | Vaccine
Experimental NIH Sudan virus vaccine protected Macaques
On Feb. 2, 2023, a National Institutes of Health research group with extensive experience studying ebolavirus countermeasures successfully…
A 19-Year-Old Adolescent with Probable Alzheimer’s Disease
On Jan. 31, 2023, a team of researchers led by the Innovation Center for Neurological Disorders and Department…
Twist Bioscience began shipping commercial product from synthetic DNA manufacturing factory of the future
On Jan. 26, 2023, Twist Bioscience announced that it had begun offering high-quality synthetic DNA using its silicon…
Risk of developing heart failure much higher in rural areas vs. urban
On Jan. 25, 2023, it was reported that adults living in rural areas of the United States have…
OHSU researchers found immune response to COVID-19 strengthens over time
On Jan. 25, 2023, researchers at Oregon Health & Science University (OHSU) reported that Immunity from COVID-19 appears…
Biotechnology | Cartoons - Original | CRISPR | Disease | Genomics | Life Science History | Therapeutics
Milestones in CRISPR
Our Milestones in CRISPR cartoon illustrates several significant achievements in the development of the technology with commentary by…
Paxlovid reduced serious risks from Omicron variants
On Jan. 10, 2023, the U.S. National Institutes of Health (NIH) reported that antiviral treatments can help reduce…
Purdue Center for Cancer Research renamed Purdue Institute for Cancer Research
On Jan. 6, 2023, the Purdue Center for Cancer Research announced it was changing its name to the…
Biotechnology | Diagnostics | Disease | FDA | Neurology | Therapeutics
FDA granted accelerated approval for Alzheimer’s disease treatment
On Jan. 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval…
Biotechnology | CRISPR | Disease | Prehistory | Therapeutics
2.6 billion-year-old ancestors of the CRISPR gene-editing tool were resurrected
On Jan. 4, 2023, an international research group announced it had for the first time reconstructed ancestors dating…
Biotechnology | Cartoons - Original | Disease | Life Science History | Polio | Therapeutics | Vaccine
Milestones in Polio
Milestones in Polio illustrates the slow but steady advancements from its clinical description and discovery to widespread infection…
Biotechnology | FDA | Oncology | Therapeutics
The FDA approves Genentech’s updated drug labeling for Xeloda (capecitabine) under Project Renewal Pilot Program
On Dec. 24, 2022, the U.S. Food and Drug Administration (FDA) approved updated labeling for Genentech’s capecitabine tablets…
Sunlenca (lenacapavir) received FDA approval as first-in-class, twice-yearly treatment option for people with multi-drug resistant HIV
On Dec. 22, 2022, Gilead Sciences announced that Sunlenca (lenacapavir), in combination with other antiretroviral(s) (ARV), had been…
Texas Biomed added to national readiness and preparedness network
On Dec. 13, 2022, Texas Biomed announced that it had been designated as a prime contractor by the…
CSL’s Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrated Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B
On Dec. 10, 2022, CSL announced data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb)…
Ebola trial candidate vaccines arrived in Uganda in record 79 days after outbreak declared
On Dec. 9, 2022, the World Health Organization (WHO) announced that the first doses of one of the…